BACKGROUND: Current public health efforts often use molecular technologies to identify and contain communicable disease networks, but not for HIV. Here, we investigate how molecular epidemiology can be used to identify highly related HIV networks within a population and how voluntary contact tracing of sexual partners can be used to selectively target these networks. METHODS: We evaluated the use of HIV-1 pol sequences obtained from participants of a community-recruited cohort (n = 268) and a primary infection research cohort (n = 369) to define highly related transmission clusters and the use of contact tracing to link other individuals (n = 36) within these clusters. The presence of transmitted drug resistance was interpreted from the pol sequences (Calibrated Population Resistance v3.0). RESULTS: Phylogenetic clustering was conservatively defined when the genetic distance between any two pol sequences was less than 1%, which identified 34 distinct transmission clusters within the combined community-recruited and primary infection research cohorts containing 160 individuals. Although sequences from the epidemiologically linked partners represented approximately 5% of the total sequences, they clustered with 60% of the sequences that clustered from the combined cohorts (odds ratio 21.7; P < or = 0.01). Major resistance to at least one class of antiretroviral medication was found in 19% of clustering sequences. CONCLUSION: Phylogenetic methods can be used to identify individuals who are within highly related transmission groups, and contact tracing of epidemiologically linked partners of recently infected individuals can be used to link into previously defined transmission groups. These methods could be used to implement selectively targeted prevention interventions.
BACKGROUND: Current public health efforts often use molecular technologies to identify and contain communicable disease networks, but not for HIV. Here, we investigate how molecular epidemiology can be used to identify highly related HIV networks within a population and how voluntary contact tracing of sexual partners can be used to selectively target these networks. METHODS: We evaluated the use of HIV-1 pol sequences obtained from participants of a community-recruited cohort (n = 268) and a primary infection research cohort (n = 369) to define highly related transmission clusters and the use of contact tracing to link other individuals (n = 36) within these clusters. The presence of transmitted drug resistance was interpreted from the pol sequences (Calibrated Population Resistance v3.0). RESULTS: Phylogenetic clustering was conservatively defined when the genetic distance between any two pol sequences was less than 1%, which identified 34 distinct transmission clusters within the combined community-recruited and primary infection research cohorts containing 160 individuals. Although sequences from the epidemiologically linked partners represented approximately 5% of the total sequences, they clustered with 60% of the sequences that clustered from the combined cohorts (odds ratio 21.7; P < or = 0.01). Major resistance to at least one class of antiretroviral medication was found in 19% of clustering sequences. CONCLUSION: Phylogenetic methods can be used to identify individuals who are within highly related transmission groups, and contact tracing of epidemiologically linked partners of recently infected individuals can be used to link into previously defined transmission groups. These methods could be used to implement selectively targeted prevention interventions.
Authors: Hong-Ha M Truong; Robert M Grant; Willi McFarland; Timothy Kellogg; Charlotte Kent; Brian Louie; Ernest Wong; Jeffrey D Klausner Journal: AIDS Date: 2006-11-14 Impact factor: 4.177
Authors: S J Hutchinson; S M Gore; D J Goldberg; D L Yirrell; J McGregor; A G Bird; A J Leigh-Brown Journal: Epidemiol Infect Date: 1999-10 Impact factor: 2.451
Authors: P J Goulder; C Brander; Y Tang; C Tremblay; R A Colbert; M M Addo; E S Rosenberg; T Nguyen; R Allen; A Trocha; M Altfeld; S He; M Bunce; R Funkhouser; S I Pelton; S K Burchett; K McIntosh; B T Korber; B D Walker Journal: Nature Date: 2001-07-19 Impact factor: 49.962
Authors: H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: Edward R Cachay; Niousha Moini; Sergei L Kosakovsky Pond; Rick Pesano; Yolanda S Lie; Heidi Aiem; David M Butler; Scott Letendre; Wm Christopher Mathews; Davey M Smith Journal: Open AIDS J Date: 2007-10-22
Authors: Manon Ragonnet-Cronin; Yunyin W Hu; Sheldon R Morris; Zhijuan Sheng; Kathleen Poortinga; Joel O Wertheim Journal: Lancet HIV Date: 2019-02-11 Impact factor: 12.767
Authors: Rebecca Rose; Susanna L Lamers; James J Dollar; Mary K Grabowski; Emma B Hodcroft; Manon Ragonnet-Cronin; Joel O Wertheim; Andrew D Redd; Danielle German; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2016-12-13 Impact factor: 2.205
Authors: Joel O Wertheim; Ben Murrell; Sanjay R Mehta; Lisa A Forgione; Sergei L Kosakovsky Pond; Davey M Smith; Lucia V Torian Journal: J Infect Dis Date: 2018-11-05 Impact factor: 5.226
Authors: Sanjay R Mehta; Sergei L Kosakovsky Pond; Jason A Young; Douglas Richman; Susan Little; Davey M Smith Journal: J Infect Dis Date: 2012-03-23 Impact factor: 5.226
Authors: Heather A Pines; Joel O Wertheim; Lin Liu; Richard S Garfein; Susan J Little; Maile Y Karris Journal: AIDS Date: 2016-11-28 Impact factor: 4.177
Authors: Britt Skaathun; Aditya S Khanna; Ethan Morgan; Samuel R Friedman; John A Schneider Journal: J Acquir Immune Defic Syndr Date: 2018-02-01 Impact factor: 3.731